KV Pharmaceutical Co.’s chief financial officer, Ronald Kanterman, stepped down Wednesday, the company said Friday.
Kanterman continues to serve as a member of the board of directors.
KV did not give a reason for the change.
Thomas McHugh, vice president of finance and corporate controller, was named interim CFO.
The company said it formed a search committee led by Interim President and Chief Executive David Van Vliet to find a permanent replacement.
On Wednesday, KV said it had begun rehiring employees to produce test batches of drugs as the company works to regain compliance with the FDA.
The U.S. Food and Drug Administration also said it gave initial approval to KV’s plan to regain compliance.
KV has been working to ramp up production again after drug recalls and an FDA investigation forced it to halt shipments.
No comments:
Post a Comment